Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02074943|
Recruitment Status : Unknown
Verified December 2014 by Jerry Shapiro, Vancouver General Hospital.
Recruitment status was: Recruiting
First Posted : February 28, 2014
Last Update Posted : December 11, 2014
|Condition or disease||Intervention/treatment||Phase|
|Androgenetic Alopecia||Biological: PRP||Not Applicable|
Platelet rich plasma (PRP) is made from your own blood by taking a sample of venous blood, placing it in a special tube, and spinning the blood in a centrifuge which is a piece of equipment used to separate the components of blood. Blood is made of red blood cells, white blood cells and platelets, while plasma, the liquid component is predominantly water but also contains clotting factors, proteins, and glucose. Platelets are small, disk shaped clear cell fragments which are a natural source of growth factors. They circulate in the blood and are involved in hemostasis which is a process which causes bleeding to stop, leading to the formation of blood clots. So-called "Platelet-rich plasma" represents the patient's own plasma that has been mechanically centrifuged to increase the concentration of platelets compared to the whole blood. The basic idea behind PRP injection is to deliver high concentrations of growth factors to the scalp, with the hope of stimulating hair regrowth.
PRP is an innovative therapy and has been used since 1987 to help promote healing in orthopedic surgery, dental surgery and dermatology. Recently, there have been reports supporting the use of PRP in the treatment of hair loss.
Androgenetic alopecia (AGA) is the most common cause of hair loss. It has very limited treatment modalities which includes minoxidil, 5-alpha reductase inhibitors and hair transplantation. Each option has its own side effects range from hypertrichosis which is excessive hair growth, possible birth defects if given to women of child bearing age, decreased libido and the possibility of prolonged impotence.
To our best knowledge, there are no double blind, randomized, placebo-controlled trials evaluating the efficacy and safety of PRP injection in treating AGA. A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient. The investigators plan to conduct a clinical trial to assess the effects and safety of PRP on AGA. The investigators also plan to identify the presence of various growth factors in PRP and their correlations in hair regrowth.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia: A Double-Blind, Randomized, Placebo Controlled Trial|
|Study Start Date :||April 2014|
|Estimated Primary Completion Date :||June 2015|
|Estimated Study Completion Date :||December 2015|
Same patient will be injected with PRP and normal saline. Each one will be inject on half head.
PRP will be inject to half head. The other half will be injected with normal saline.
- The degree of hair regrowth based on the hair regrowth score (RGS) for each side of scalp. [ Time Frame: 16 weeks ]
- Changes in hair count and caliber. Changes in hair count and caliber [ Time Frame: 16 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02074943
|Contact: Jerry Shapiro, MD||604-875-5151||Jerry.Shapiro@vch.ca|
|The Skin Care Center, Vancouver General Hospital||Recruiting|
|Vancouver, Canada, V5Z 4E8|
|Contact: Jerry Shapiro, MD 604-875-5151 Jerry.Shapiro@vch.ca|
|Principal Investigator:||Jerry Shapiro, MD||Professor|